
|Videos|March 11, 2022
Dr. Oh gives overview of oligometastatic prostate cancer and emergent therapies
Author(s)Urology Times staff
“We have new therapies, both AR-targeted therapies, as well as the use of SBRT, or targeted radiotherapy, that have changed the landscape,” says William K. Oh, MD.
Advertisement
In this video, William K. Oh, MD, discusses why oligometastatic prostate cancer is a “hot topic” in urology right now, and what therapies are expected to emerge in the near future to help manage this complex disease state. These concepts stem from Oh’s presentation, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












